How fast IVIG works depends almost entirely on what condition is being treated. In some cases, like immune thrombocytopenia (ITP), measurable improvement can begin within hours. In others, like chronic inflammatory demyelinating polyneuropathy (CIDP), meaningful recovery can take weeks or even months of repeated infusions. There is no single answer, but there are well-documented timelines for the most common conditions.
What IVIG Does in Your Body
IVIG is a concentrated dose of antibodies collected from thousands of donors and delivered directly into your bloodstream through an IV. Once infused, these antibodies work in several ways at once. They can bind directly to viruses, bacteria, or toxins and neutralize them. They can also calm an overactive immune system by dialing down the activity of certain immune cells, blocking the receptors that trigger inflammation, and expanding the population of regulatory cells that keep immune responses in check.
The infused antibodies have a long lifespan in the body. The median half-life of IgG after infusion is about 36 days, meaning half the infused antibodies are still circulating more than a month later. This is why IVIG is typically given on a 3- or 4-week schedule for chronic conditions. But a long half-life doesn’t mean slow results. The immune-modulating effects can kick in well before the antibodies are cleared.
ITP: Hours to Days
Immune thrombocytopenia, where the immune system destroys platelets and increases bleeding risk, is where IVIG works fastest. In a randomized trial of children with ITP, 55% had their platelet counts rise to a safer level within just 8 hours of starting the infusion. By 24 hours, average platelet counts had climbed to around 55,000 per microliter (up from dangerously low levels). By 72 hours, the average reached roughly 143,000, which is within the normal range.
The catch is that this improvement often doesn’t last. By day 21, average platelet counts in the same study had dropped back down to about 40,000. This reflects how IVIG works in ITP: it temporarily overwhelms the receptors that immune cells use to grab and destroy platelets, giving your body a window to recover. For acute bleeding episodes, that fast but temporary response is exactly what’s needed.
Myasthenia Gravis: Days to Two Weeks
In myasthenia gravis, a condition where the immune system attacks the connections between nerves and muscles, IVIG typically produces improvement within a few days to one or two weeks. It’s considered a “rapid induction” therapy alongside plasma exchange, and both are used when symptoms are severe or worsening quickly, such as during a myasthenic crisis affecting breathing muscles. The speed here falls in a middle range: not as immediate as in ITP, but fast enough to be useful in urgent situations.
Guillain-Barré Syndrome: Weeks, With No Guarantee
Guillain-Barré syndrome (GBS), where the immune system attacks the nerves controlling movement and sensation, has a less predictable timeline. IVIG is a standard treatment, but up to 50% of patients who receive it show no improvement in symptoms after four weeks. For those who do respond, recovery is gradual. The nerve damage caused by GBS takes time to heal regardless of treatment, so IVIG’s role is more about stopping further immune attack than producing rapid symptom relief. Many patients continue to improve over months as nerves slowly repair themselves.
CIDP: Months of Gradual Gains
Chronic inflammatory demyelinating polyneuropathy (CIDP) is the chronic counterpart to GBS, and IVIG response here is measured in months, not days. In a study tracking CIDP patients who responded to IVIG therapy, hand grip strength reached its maximum improvement at an average of about 20 weeks (roughly 5 months). Other muscle groups took longer: elbow strength peaked around 27 weeks, ankle strength at 28 weeks, and knee strength at nearly 38 weeks.
Overall, about 70% of responding patients had reached their maximum strength gains across all measures by 300 days (roughly 10 months). This doesn’t mean you’d notice nothing for months. Improvement is incremental, building with each infusion cycle. But if you’re starting IVIG for CIDP, the realistic expectation is a slow upward trajectory rather than a dramatic early change. Some patients require hundreds of grams of IVIG over 20 to 37 weeks of treatment to reach their best response.
Why Some People Respond Faster Than Others
Even within the same condition, individual responses vary widely. Several factors influence how quickly IVIG takes effect.
- Disease severity at the start. Higher levels of inflammation can actually work against you. Severe inflammation increases the leakiness of blood vessels, allowing the infused antibodies to seep out of the bloodstream and into surrounding tissues. This reduces the amount of IVIG circulating where it’s needed and can result in subtherapeutic levels despite a standard dose.
- Age and body composition. These affect how the drug distributes through the body and how quickly it’s broken down. Younger patients with certain conditions, like Kawasaki disease, are actually more likely to be resistant to IVIG treatment.
- Protein levels in the blood. Low albumin (a key blood protein) reflects protein leakage from inflamed blood vessels and correlates with poorer IVIG response.
- Genetic variation. Differences in the receptors that interact with antibodies, and in the cellular recycling system that protects antibodies from being broken down too quickly, can alter how long infused IgG stays active in your body. Some people simply metabolize the treatment faster than others.
- Inflammatory markers. Elevated markers of inflammation at baseline, including C-reactive protein and high white blood cell counts, have been associated with slower or weaker responses.
What to Expect During Treatment
Each IVIG infusion session can take several hours. The infusion rate usually starts slow and is gradually increased as your care team monitors for reactions. If you experience discomfort during or after a session (headaches, chills, or nausea are among the more common side effects), the rate and dose can be adjusted for future infusions.
For chronic conditions like CIDP or primary immunodeficiency, IVIG is given on a recurring schedule, typically every 3 to 4 weeks. Trough levels of IgG (the lowest point between infusions) remain relatively stable over time on these schedules, which is the goal for long-term management. For acute conditions like GBS or a myasthenic crisis, IVIG is usually given as a short course over several consecutive days.
If you’re not seeing improvement within the expected window for your condition, that doesn’t necessarily mean IVIG has failed entirely. Some conditions require a second course or a switch to an alternative therapy. The decision to continue, adjust, or change treatment depends on the specific condition, how much time has passed, and whether there are any partial signs of response.